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Abstract
Background: Although severe oral opportunistic infections decreased with the implementation of highly active
antiretroviral therapy, periodontitis is still a commonly described problem in patients infected with human
immunodeficiency virus (HIV). The objective of the present investigation was to determine possible differences in
periodontal parameters between antiretroviral treated and untreated patients.
Methods: The study population comprised 80 patients infected with HIV divided into two groups. The first group
was receiving antiretroviral therapy while the second group was therapy naive. The following parameters were
examined: probing pocket depth, gingival recession, clinical attachment level, papilla bleeding score, periodontal
screening index and the index for decayed, missed and filled teeth. A questionnaire concerning oral hygiene,
dental care and smoking habits was filled out by the patients.
Results: There were no significant differences regarding the periodontal parameters between the groups except in
the clinical marker for inflammation, the papilla bleeding score, which was twice as high (P < 0.0001) in the
antiretroviral untreated group (0.58 ± 0.40 versus 1.02 ± 0.59). The participants of this investigation generally
showed a prevalence of periodontitis comparable to that in healthy subjects. The results of the questionnaire were
comparable between the two groups.
Conclusion: There is no indication for advanced periodontal damage in HIV-infected versus non-infected patients
in comparable age groups. Due to their immunodeficiency, HIV-infected patients should be monitored closely to
prevent irreversible periodontal damage. Periodontal monitoring and early therapy is recommended independent
of an indication for highly active antiretroviral therapy.
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Introduction
The therapy of patients infected with the human immu-
nodeficiency virus (HIV) dates back to 1986, when the
monotherapy, azidothymidine, was introduced. At that
time, oral manifestations of the immune deficiency syn-
drome were used, alongside other diagnostic parameters,
as markers for disease progression. Thus, oral candidia-
sis correlated with a progressive immune deficiency,
resulting in Candida esophagitis, defines the progression
to acquired immunodeficiency syndrome (AIDS; Center
for Disease Control Classification System; Category C).
In 1983, 13 years after detection of the virus, an effec-
tive long-term therapy was established by combining up
to three antiretroviral substances. After the implementa-
tion of this highly active antiretroviral therapy (HAART)
in 1996 the morbidity and mortality of HIV-infected
patients decreased dramatically. The number of oppor-
tunistic infections, like oral Kaposi’s sarcoma, oral can-
didiasis, necrotizing periodontal diseases and hairy
leukoplakia, also decreased [1,2]. However, these infec-
tions are still evidence of immunological damage in
treated and untreated HIV-positive patients. Necrotizing
periodontal diseases especially may indicate a CD4+ cell
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opportunistic infections, including oral manifestations,
international medical associations developed guidelines
for starting an antiretroviral treatment. For non-sympto-
matic patients, these guidelines recommend starting
treatment when the patient has a CD4+ cell count
below 350 cells/μL, depending on cofactors such as viral
load, age and clinical progression [4].
For a dentist involved in the care of an HIV patient,
recurrent mucosal and/or gingival infections, for exam-
ple, human papilloma virus, as well as gingival inflam-
matory processes and necrotizing ulcerative
periodontitis, still remain a problem. The quantitative
restoration of the immune system and an increase of
the CD4+ cell count under HAART do not always cor-
relate with a qualitative obtainment of immunological
skills. The degree of immunological damage and the
potential for recovery under therapy are not always pre-
dictable. Under these conditions, oral lesions (such as
candidiasis) are still a marker for immunological incom-
petence. Nevertheless, the risk of developing severe oral
opportunistic infections decreases with a sufficient anti-
retroviral therapy [1,5].
Most studies and investigations concerning the preva-
lence and therapy of periodontal diseases in HIV-infec-
tion go back to the pre-HAART era or end shortly after
this period. Subsequent studies and investigations evalu-
ated either blood parameters like cytokine expression in
HIV-infected patients [6] or compared the periodontal
status of HIV-positive with HIV-negative patients [7].
Inflammatory markers, particularly cytokine levels, have
become more relevant in periodontal diagnosis and
treatment. HIV-positive patients show higher levels of
interleukin-18 and interleukin-2 expression than patients
with healthy periodontal conditions, as well as higher
grades of oral inflammation. It has been documented
that HIV-positive patients have more severe grades of
periodontitis compared with HIV-negative patients with
periodontitis [6]. Until now, there were no studies avail-
able that compared the dental and periodontal state
between treated and untreated HIV-infected patients.
Therefore, the aim of this investigation was to investi-
gate if there are any differences regarding the prevalence
and severity of periodontal disease between untreated
HIV-infected patients and patients under treatment with
a viral load under the limit of detection of 40 cop/mL.
Materials and methods
Sample
The study protocol was approved by the Ethical Com-
mittee of Hannover Medical School (No. 4201) and per-
formed with the understanding and written consent of
each subject. The study population comprised 80 HIV-
infected patients (7 women and 73 men) between 21
and 60 years of age (mean 41.7 years ± 7.2). The partici-
pants were divided into two groups: patients undergoing
HAART (HAART group, n = 40) and antiretroviral
untreated patients (naïve group, n = 40).
Inclusion criteria for patients were full age (18 years
or older); a stable antiretroviral treatment (HAART)
with a viral load below limit of detection (40 cop/mL)
for the last six months in the HAART-group; and a
CD4+ cell count over 350 cells/μL and no antiretroviral
treatment in the naive-group (following international
guidelines). Exclusion criteria included pregnancy; dia-
betes mellitus; immunosuppressed patients; and a
detectable viral load in the HAART-group.
Clinical examination
The patients were either examined in the Department of
Conservative Dentistry, Periodontology and Preventive
Dentistry of the Hannover Medical School or in a pri-
vate specialized practice (Georgstrasse, Hannover, Ger-
many). All clinical examinations were carried out by a
single experienced dentist using the World Health Orga-
nization (WHO) periodontal probe (WHO 2002) to
ensure consistency of measurements. A periodontal
examination was performed, which included a number
of parameters (see Table 1 for full definitions). The
probing pocket depth (PPD) and gingival recession (GR)
were recorded at four sites per tooth (mesio-buccal,
disto-buccal, disto-oral and mesio-oral). The clinical
attachment level (CAL) was calculated as the sum of
P P Da n dG R .T h ep a p i l l ab l e e d i n gs c o r e( P B S )i s
defined as the occurrence of bleeding after a gentle
approximal insertion of a periodontal probe. A PBS
score of 0 to 5 is determined on all papillae anterior to
the second molars and omits readings on the buccal and
lingual gingival margins. The periodontal screening
index (PSI) is a WHO accepted detection system for
periodontal disease and is subdivided into five codes.
Code 0 shows healthy circumstances, codes 1 and 2
indicate gingivitis, and codes 3 and 4 indicate periodon-
titis (see Table 1 for full definitions). Finally, the DMF-
T index describes the total count of decayed missed and
filled teeth except the third molars.
Information concerning demographic features, general
health, HIV infection history and immunological status
were obtained from an anamnestic questionnaire and
patients’ medical records. Furthermore, the patients
filled out a questionnaire regarding their smoking habits,
any drug abuse and oral hygiene.
Statistical analysis
Power and sample sizes were calculated using nQuery
Advisor 6.0. (Statistical Solutions, Saugas, MA, USA). A
power calculation revealed that our sample size of 80
had 80% power. Documentation and analysis of the data
Fricke et al. European Journal of Medical Research 2012, 17:2
http://www.eurjmedres.com/content/17/1/2
Page 2 of 6was performed with the data processing program SPSS/
PC Version 17.0. for Windows (SPSS Inc., Chicago, IL,
USA). The statistical unit for all tests was each indivi-
dual subject; median and range values were calculated
for all parameters. A non parametric test (Mann-Whit-
ney-Test) with a significance level of P < 0.05 was used
to analyze the differences between the two groups. The
analysis of the patients’ questionnaires was performed
with a Chi-square test.
Results
Baseline data showed a viral load of 50,636 ± 68,382
cop/mL in the naïve group and < 40 cop/mL in the
HAART-group. The CD4+ cell count was 500.5 ± 241.4
cells/μL in the naïve group and 627.5 ± 316.3 cells/μL
in the HAART group.
The demographic data showed a mean age of 44 ± 6.12
years with a duration of infection of 14 ± 6.31 years in
the HAART group versus a mean age of 36 ± 8.48 years
and a duration of infection of 6 ± 4.24 years in the naïve
group. There were no significant differences (P > 0.05) in
age or CD4+ cell count between the groups, while the
duration of infection showed a P-value of 0.001. For the
HAART group, data concerning drug classes, therapy
regimen, nadir and duration of HAART were analyzed.
The results are shown in Table 2. Their medical histories
showed that 15% (n = 6) of the treated group had co-
infection with hepatitis C. There were no patients with a
hepatitis C co-infection in the naïve group.
Their smoking habits showed no significant difference
between the groups (HAART group, 61% smokers and
39% non-smokers; naive-group, 65.4% smokers and
34.6% non-smokers). Smoking had a significant influ-
ence on the parameter CAL (P = 0.039) independently
of the group, but did not influence any other measured
periodontal parameters.
The results of the questionnaire showed no significant
difference in oral hygiene behavior between the groups
(Table 3).
As shown in Figure 1, periodontitis (PSI codes 3 and
4) was diagnosed in 70.2% of the HAART group and
73.7% of the naive-group.
Table 1 Periodontal and dental parameters.
Parameter Description
PPD Distance between the gingiva and the bottom of the periodontal sulcus, expressed in millimeters
GR Distance between the gingiva and enamel-cemetum-junction, expressed in millimeters
CAL Addition of PPD and GR
PBS Classified in increasing order of inflammation (grade 0-5), based on the strength of bleeding after gentle probing of the gingiva
0 = healthy gingiva; no bleeding
1 = edematous, reddened gingiva; no bleeding
2 = bleeding without flow
3 = bleeding with flow along gingival margin
4 = copious bleeding
5 = severe inflammation, marked redness and edema, tendency for spontaneous bleeding
PSI Divided into five codes and estimates the clinical parameters of plaque, bleeding and pocket depth.
Code 0 = colored area of the probe remains visible in all the pockets of the sextant. No calculus and no defective margins on
restorations. No bleeding is evident on probing.
Code 1 = similar to Code 0, but bleeding is detected on probing.
Code 2 = calculus, above or below the marginal gingiva, is detected. Also used to indicate defective restorative margins. Colored area
of the probe is still completely visible.
Code 3 = colored area of the probe is only partly visible in at least one pocket of the sextant indicating a PPD between 3.5 mm and
5.5 mm.
Code 4 = colored area of the probe is not visible in at least one pocket of the sextant, indicating a PPD more than 5.5 mm.
DMF-T Total count of teeth which are decayed, missing and filled (except third molars)
CAL: clinical attachment level; DMF-T: decayed-missed-filled-teeth; GR: gingival recession; PBS: papilla bleeding score; PPD: probing pocket depth; PSI: periodontal
screening index.
Table 2 Antiretroviral parameters (HAART group).
Parameter Percentage of group
Drug classes NRTI + PI 52.5% (n = 21)
NRTI + NNRTI 27.5% (n = 11)
NRTI + NNRTI + PI 5.0% (n = 2)
PI 2.5% (n = 1)
NRTI 12.5% (n = 5)
Therapy regimen First line ART 68.3%
Second/third line therapy 31.7%
Nadir (CD4+) 275.6 ± 141.3 cells/μL
Duration of HAART 9.2 ± 4.3 years
ART: antiretroviral therapy; HAART: highly active antiretroviral therapy; NNRTI:
non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside analog
reverse-transcriptase inhibitors; PI: protease inhibitor.
Fricke et al. European Journal of Medical Research 2012, 17:2
http://www.eurjmedres.com/content/17/1/2
Page 3 of 6There were no significant differences between the
groups regarding PSI (HAART group = 2.7 ± 0.84; naïve
group = 2.9 ± 0.70), CAL (HAART group = 3.6 ± 1.96
mm; naïve group = 3.2 ± 1.7 mm) or DMF-T (HAART
group = 16.46 ± 6.63; naïve group = 14.57 ± 5.75). As
shown in Figure 2, the values for PBS were significantly
higher (P < 0.0001) in the naïve group (1.02 ± 0.59)
compared with the HAART group (0.58 ± 0.40).
Discussion
The aim of this investigation was to investigate if there
are differences in the periodontal status of HIV-infected
patients with and without antiretroviral treatment. Pre-
vious studies have primarily compared HIV-infected
patients with uninfected patients. Our results show a
significantly higher level of gingival inflammation in the
antiretroviral untreated group of patients although these
patients were younger and had a shorter duration of
HIV infection. No other examined periodontal para-
meters showed any significant difference. The demo-
graphic data showed an inhomogeneous distribution of
gender in both groups. This difference is reflected by
the epidemiological data of the Robert Koch Institute
and results from the high-risk group, of men having sex
with men, that represents the majority of HIV-infected
patients in industrialized countries [8]. The difference of
patients’ age and duration of infection between the
groups is consistent with data of other studies, where
the median age of starting an antiretroviral treatment
was 36 years [9].
For comparable results with HIV-negative patients, a
third group of 40 people should have been included to
guarantee consistent methods of clinical examination.
However, the 2006 4th German Oral Health Study is an
appropriate study to use to match our patients with
healthy subjects [10]. That study examined the oral
health status of different age groups, and their group of
35 to 45 years of age is comparable with the present
Table 3 Oral hygiene behavior, concerning technique,
frequency and duration.




Manually and mechanically 19.5 15.0
Frequency
Once daily or less 14.6 27.5
Twice daily 70.7 65.0
More than twice daily 14.7 7.5
Duration
< 1 minute 22 26,5
2 minutes 46.3 53.5
3 minutes or more 31.7 20
Figure 1 Percentage occurrence of periodontitis based on the periodontal screening index coding.
Figure 2 Mean values and standard deviation of the papilla
bleeding score.
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moderate to severe periodontitis (PSI codes 3 and 4),
with a DMF-T ranging between 12.9 and 15.6 [10].
These similar results of the present and cited study are
evidence for decreasing oral manifestation and revised
periodontal conditions in HIV-infected patients. How-
ever, a prevalence of 73.2% illustrates the importance of
adequate periodontal monitoring and early effective per-
iodontal therapy. The almost similar prevalence between
healthy and HIV-infected subjects should not hide the
fact that not only clinical parameters like PSI and indivi-
dual dental care are predictors for the status and pro-
gression of periodontal disease in HIV-infected patients.
Immunological competence is a marker for success or
failure of the antiretroviral therapy as well as the risk of
acquiring opportunistic infections. A dentist should clo-
sely observe patients on second and third line therapy
where an immunological failure has already occurred.
Alongside these clinical results, all patients filled out a
questionnaire regarding the frequency and duration of
their oral hygiene as well as their smoking habits.
About two-thirds of the patients were smokers, which
is described as a main risk factor for periodontal dis-
eases. This study also documents that smoking is an
enhancer for attachment loss of periodontal tissues. As
a matter of fact, smoking is associated with periodontitis
[11] and the risk of suffering from moderate to severe
chronic periodontitis is two to eight times higher in
people who smoke compared with non-smoking indivi-
duals [11-13].
Table 3 shows no significant differences in the oral
hygiene behavior between the groups. The results are
based on the answers of the patients. The self-reported
frequency and duration of brushing are subjective and
might be positively influenced by generally accepted
guidelines and recommendations. Therefore it can be
speculated that the information provided by the patients
might be biased.
Most of the published studies regarding HIV and peri-
odontitis in the last 10 years differ between HIV-positive
and -negative patients [14-16] or refer to the prevalence
of oral opportunistic infections in underdeveloped coun-
tries [17-19]. Presently and in the future there will be
more patients in industrialized countries who did not
experience the pre-HAART era and should therefore
not suffer from any opportunistic infections, especially
from oral and irreversible periodontal diseases. The
examined group under HAART in this investigation
showed a mean period of HIV-infection of 14 years.
Based on the implementation of HAART in the year
1996, the occurrence of oral adverse events has already
decreased.
This investigation primarily focused on clinical para-
meters of gingival and/or periodontal variation in the
examined groups. Further studies regarding laboratory
parameters, particularly inflammatory markers and their
influence on periodontal diseases in HIV-infected
patients with and without antiretroviral treatment, are
needed to give a more detailed explanation for the
results of this investigation.
Conclusion
The value for the PBS was almost twice as high in the
naïve group compared with the HAART group. Despite
the fact that the naïve group had a shorter mean period
of HIV-infection and a lower mean age, it showed a
higher level of periodontal inflammation, while the pro-
gression of periodontal damage was similar in both
groups. An explanation for this higher grade of inflam-
mation can only partially be given and needs further
investigation to correlate clinical and immunological
data in treated and untreated HIV-infected patients and
their periodontal status. It may be concluded that
HAART seems to avoid progressive periodontal damage
even in subjects with a longer period of HIV-infection.
Comparing the periodontal conditions of HIV-positive
patients in the present study with a HIV-negative Ger-
man population (DMS IV [10]), there is no difference in
severity and prevalence of periodontal diseases. Smoking
has a strong influence on the progression of periodontal
disease independent of the immunological status.
A periodontal diagnosis and therapy is recommended
independent of an indication for HAART in both
groups. The high prevalence of periodontitis strongly
suggests the need for prevention, early diagnosis and
adequate therapy of periodontitis.
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